Table 4.
Change from baseline in HIV inhibition by vaginal fluid based on IVR and community state type (CST).
| IVR and CST group | Pre-insertion baseline | Month 1 | Month 3 | p value | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean | SD | Median | N | Mean | SD | Median | N | Mean | SD | Median | ||
| TFVLNG IVR (continuous and cyclic cohorts combined) | |||||||||||||
| CST IVA/B | 18 | -2.46 | 28.85 | 4.21 | 17 | 94.87 | 13.69 | 98.75 | 19 | 57.71 | 47.63 | 74.42 | < 0.01 |
| LbD | 18 | 16.14 | 15.85 | 14.38 | 13 | 93.88 | 6.63 | 95.61 | 11 | 95.68 | 6.15 | 97.18 | < 0.01 |
| Placebo IVR (continuous and cyclic cohorts combined) | |||||||||||||
| CST IVA/B | 4 | -7.57 | 29.96 | -15.27 | 5 | -3.04 | 54.69 | 32.34 | 5 | -28.79 | 48.03 | -20.68 | 0.48 |
| LbD | 6 | 2.45 | 11.5 | 5.9 | 5 | -26.54 | 82.45 | -6.94 | 5 | -0.85 | 31.91 | 4.99 | 0.81 |